SCP
MRNA icon

Sender Company & Partners’s Moderna MRNA Stock Holding History

Sender Company & Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,751
Closed -$530K – 93
2024
Q4 		$530K Buy
+12,751
New +$609K 0.48% 43
2023
Q3 		– Sell
-3,503
Closed -$426K – 39
2023
Q2 		$426K Sell
3,503
-989
-22% -$132K 0.55% 12
2023
Q1 		$690K Buy
+4,492
New +$741K 0.73% 17

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sender Company & Partners's MRNA Position: Q1 2025 in Review

Sender Company & Partners sold out of Moderna (MRNA) in Q1 2025, closing a stake of 12,751 shares — an estimated $530K sold.

Sender Company & Partners first reported a position in MRNA in Q1 2023 and held it in 3 quarters. The position peaked at $690K in Q1 2023. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • Sender Company & Partners reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • Sender Company & Partners sold 12,751 Moderna shares in Q1 2025, an estimated $530K.
  • Sender Company & Partners first reported a position in Moderna in Q1 2023 and held it in 3 quarters.
  • Sender Company & Partners's Moderna position peaked at $690K in Q1 2023.
  • 693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on Sender Company & Partners's 13F filing for Q1 2025, filed 16 May 2025.